Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crossover study of dapagliflozin, exenatide, and their combination for albuminuria in type 2 diabetes
NL-OMON46820Phase 3Completed
- Sponsor
- Martini Ziekenhuis
- Start
- Jan 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dapagliflozin and exenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Martini Ziekenhuis. Primary endpoint: Change in albuminuria from baseline at the end of each treatment period. Started Jan 2019; status: completed.
02
Drugs
dapagliflozinexenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON46820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46820.